Etamivan

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug^[1] related to nikethamide. It was mainly used in the treatment of barbiturate overdose^[2] and chronic obstructive pulmonary disease,^[3] but has now largely fallen into disuse.

Etamivan

Clinical data
Trade names	Analepticon
ATC code	R07AB04 (WHO)
Identifiers
IUPAC name N,N-Diethyl-4-hydroxy-3-methoxybenzamide
CAS Number	304-84-7 Y
PubChem CID	9363
DrugBank	DB08989 N
ChemSpider	8996 N
UNII	M44O63YPV9
KEGG	D04080 Y
CompTox Dashboard (EPA)	DTXSID3023007
ECHA InfoCard	100.005.599
Chemical and physical data
Formula	C12H17NO3
Molar mass	223.272 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(CC)C(=O)c1ccc(O)c(OC)c1
InChI InChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3 N Key:BQJODPIMMWWMFC-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.^[4]